BCHE and early-onset autosomal dominant Alzheimer disease: The known cholinesterase inhibitor rivastigmine, used for Alzheimer’s disease (AD) treatment, is an example of a semi-synthetic drug developed based on the naturally occurring cholinesterase inhibitor physostigmine scaffold [5].